How would you manage a patient with EGFR mutant adenocarcinoma of the lung on erlotinib with a single site of disease progression, but otherwise well-controlled disease?
Would you stop the Tarceva at this point?
Answer from: Medical Oncologist at Academic Institution
This is a point of controversy. There are multiple reasonable options to consider for such a patient:
Keep going with tarceva and follow the lesion carefully. The NCCN guidelines actually acknowledge this approach for asymptomatic disease.
Use SRS or some other locally ablati...
Sign in or Register to read more